Literature DB >> 31054263

Hyperoxia speeds pulmonary oxygen uptake kinetics and increases critical power during supine cycling.

Richie P Goulding1, Denise M Roche1, Simon Marwood1.   

Abstract

NEW
FINDINGS: What is the central question of this study? Critical power is a fundamental parameter defining high-intensity exercise tolerance and is related to the phase II time constant of pulmonary oxygen uptake kinetics ( τ V ̇ O 2 ). To test whether this relationship is causal, we assessed the impact of hyperoxia on τ V ̇ O 2 and critical power during supine cycle exercise. What is the main finding and its importance? The results demonstrate that hyperoxia increased muscle oxygenation, reduced τ V ̇ O 2 (i.e. sped up the oxygen uptake kinetics) and, subsequently, increased critical power when compared with normoxia. These results therefore suggest that τ V ̇ O 2 is a determinant of the upper limit for steady-state exercise, i.e. critical power. ABSTRACT: The present study determined the impact of hyperoxia on the phase II time constant of pulmonary oxygen uptake kinetics ( τ V ̇ O 2 ) and critical power (CP) during supine cycle exercise. Eight healthy men completed an incremental test to determine maximal oxygen uptake and the gas exchange threshold. Eight separate visits followed, whereby CP, τ V ̇ O 2 and absolute concentrations of oxyhaemoglobin ([HbO2 ]; via near-infrared spectroscopy) were determined via four constant-power tests to exhaustion, each repeated once in normoxia and once in hyperoxia (fraction of inspired O2  = 0.5). A 6 min bout of moderate-intensity exercise (70% of gas exchange threshold) was also undertaken before each severe-intensity bout, in both conditions. Critical power was greater (hyperoxia, 148 ± 29 W versus normoxia, 134 ± 27 W; P = 0.006) and the τ V ̇ O 2 reduced (hyperoxia, 33 ± 12 s versus normoxia, 52 ± 22 s, P = 0.007) during severe exercise in hyperoxia when compared with normoxia. Furthermore, [HbO2 ] was enhanced in hyperoxia compared with normoxia (hyperoxia, 67 ± 10 μm versus normoxia, 63 ± 11 μm; P = 0.020). The τ V ̇ O 2 was significantly related to CP in hyperoxia (R2  = 0.89, P < 0.001), but no relationship was observed in normoxia (r = 0.07, P = 0.68). Muscle oxygenation was increased, τ V ̇ O 2 reduced and CP increased in hyperoxia compared with normoxia, suggesting that τ V ̇ O 2 is an independent determinant of CP. The finding that τ V ̇ O 2 was related to CP in hyperoxia but not normoxia also supports this notion.
© 2019 The Authors. Experimental Physiology © 2019 The Physiological Society.

Entities:  

Keywords:  critical power; hyperoxia; oxygen uptake kinetics

Mesh:

Year:  2019        PMID: 31054263     DOI: 10.1113/EP087599

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  5 in total

1.  Bioenergetic Mechanisms Linking V˙O2 Kinetics and Exercise Tolerance.

Authors:  Richie P Goulding; Harry B Rossiter; Simon Marwood; Carrie Ferguson
Journal:  Exerc Sport Sci Rev       Date:  2021-10-01       Impact factor: 6.642

Review 2.  The role of vascular function on exercise capacity in health and disease.

Authors:  David C Poole; Brad J Behnke; Timothy I Musch
Journal:  J Physiol       Date:  2020-03-03       Impact factor: 5.182

3.  Factors determining training-induced changes in V̇O2max, critical power, and V̇O2 on-kinetics in skeletal muscle.

Authors:  Bernard Korzeniewski; Harry B Rossiter
Journal:  J Appl Physiol (1985)       Date:  2020-11-19

4.  Impact of supine versus upright exercise on muscle deoxygenation heterogeneity during ramp incremental cycling is site specific.

Authors:  Richie P Goulding; Dai Okushima; Yoshiyuki Fukuoka; Simon Marwood; Narihiko Kondo; David C Poole; Thomas J Barstow; Shunsaku Koga
Journal:  Eur J Appl Physiol       Date:  2021-02-11       Impact factor: 3.078

5.  The ramp and all-out exercise test to determine critical power: validity and robustness to manipulations in body position.

Authors:  Richie P Goulding; Denise M Roche; Simon Marwood
Journal:  Eur J Appl Physiol       Date:  2021-06-18       Impact factor: 3.078

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.